Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Monoamine Oxidase B Total Distribution Volume in the Prefrontal Cortex of Major Depressive Disorder: An [11C]SL25.1188 Positron Emission Tomography Study.

Moriguchi S, Wilson AA, Miler L, Rusjan PM, Vasdev N, Kish SJ, Rajkowska G, Wang J, Bagby M, Mizrahi R, Varughese B, Houle S, Meyer JH.

JAMA Psychiatry. 2019 Mar 6. doi: 10.1001/jamapsychiatry.2019.0044. [Epub ahead of print]

PMID:
30840042
2.

Normal glutathione levels in autopsied brain of chronic users of heroin and of cocaine.

Tong J, Fitzmaurice PS, Moszczynska A, Rathitharan G, Ang LC, Meyer JH, Mizrahi R, Boileau I, Furukawa Y, McCluskey T, Sailasuta N, Kish SJ.

Drug Alcohol Depend. 2018 Sep 1;190:20-28. doi: 10.1016/j.drugalcdep.2018.05.021. Epub 2018 Jun 23.

PMID:
29960919
3.

Comparative hazards of acute myocardial infarction among hospitalized patients with methamphetamine- or cocaine-use disorders: A retrospective cohort study.

Callaghan RC, Halliday M, Gatley J, Sykes J, Taylor L, Benny C, Kish SJ.

Drug Alcohol Depend. 2018 Jul 1;188:259-265. doi: 10.1016/j.drugalcdep.2018.03.030. Epub 2018 Apr 26.

PMID:
29793190
4.

Elevated monoamine oxidase A activity and protein levels in rodent brain during acute withdrawal after chronic intermittent ethanol vapor exposure.

Matthews BA, Tong J, Attwells S, Xu X, Le A, Kish SJ, Meyer JH.

Drug Alcohol Depend. 2018 Apr 1;185:398-405. doi: 10.1016/j.drugalcdep.2017.11.036. Epub 2018 Feb 5.

PMID:
29549852
5.

Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.

Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang LC, Boileau I, Guttman M, Hornykiewicz O, Kish SJ.

Brain. 2017 Sep 1;140(9):2460-2474. doi: 10.1093/brain/awx172.

PMID:
29050386
6.

Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder.

Attwells S, Setiawan E, Wilson AA, Rusjan PM, Mizrahi R, Miler L, Xu C, Richter MA, Kahn A, Kish SJ, Houle S, Ravindran L, Meyer JH.

JAMA Psychiatry. 2017 Aug 1;74(8):833-840. doi: 10.1001/jamapsychiatry.2017.1567.

7.

Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications.

Sitte HH, Pifl C, Rajput AH, Hörtnagl H, Tong J, Lloyd GK, Kish SJ, Hornykiewicz O.

Eur J Neurosci. 2017 May;45(10):1356. doi: 10.1111/ejn.13573. No abstract available.

PMID:
28523903
8.

Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls.

Rabin RA, Barr MS, Goodman MS, Herman Y, Zakzanis KK, Kish SJ, Kiang M, Remington G, George TP.

Neuropsychopharmacology. 2017 Oct;42(11):2259-2271. doi: 10.1038/npp.2017.85. Epub 2017 Apr 26.

9.

Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications.

Sitte HH, Pifl C, Rajput AH, Hörtnagl H, Tong J, Lloyd GK, Kish SJ, Hornykiewicz O.

Eur J Neurosci. 2017 Jan;45(1):192-197. doi: 10.1111/ejn.13435. Epub 2016 Nov 11. Erratum in: Eur J Neurosci. 2017 May;45(10 ):1356.

PMID:
27741357
10.

Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain.

Tong J, Mizrahi R, Houle S, Kish SJ, Boileau I, Nobrega J, Rusjan PM, Wilson AA.

J Cereb Blood Flow Metab. 2017 Nov;37(11):3635-3639. doi: 10.1177/0271678X16668890. Epub 2016 Oct 1.

11.

Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Kish SJ, Boileau I, Callaghan RC, Tong J.

Eur J Neurosci. 2017 Jan;45(1):58-66. doi: 10.1111/ejn.13363. Epub 2016 Sep 5. Review.

12.

A marked contrast between serotonergic and dopaminergic changes in dopa-responsive dystonia.

Furukawa Y, Rajput AH, Tong J, Tomizawa Y, Hornykiewicz O, Kish SJ.

Neurology. 2016 Sep 6;87(10):1060-1. doi: 10.1212/WNL.0000000000003065. Epub 2016 Aug 3. No abstract available.

13.

Heightened Dopaminergic Response to Amphetamine at the D3 Dopamine Receptor in Methamphetamine Users.

Boileau I, Payer D, Rusjan PM, Houle S, Tong J, McCluskey T, Wilson AA, Kish SJ.

Neuropsychopharmacology. 2016 Dec;41(13):2994-3002. doi: 10.1038/npp.2016.108. Epub 2016 Jun 29.

14.

Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [11C]CURB.

Boileau I, Mansouri E, Williams B, Le Foll B, Rusjan P, Mizrahi R, Tyndale RF, Huestis MA, Payer DE, Wilson AA, Houle S, Kish SJ, Tong J.

Biol Psychiatry. 2016 Nov 1;80(9):691-701. doi: 10.1016/j.biopsych.2016.04.012. Epub 2016 Apr 25.

15.

Do glutathione levels decline in aging human brain?

Tong J, Fitzmaurice PS, Moszczynska A, Mattina K, Ang LC, Boileau I, Furukawa Y, Sailasuta N, Kish SJ.

Free Radic Biol Med. 2016 Apr;93:110-7. doi: 10.1016/j.freeradbiomed.2016.01.029. Epub 2016 Feb 1.

PMID:
26845616
16.

D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia.

Payer DE, Guttman M, Kish SJ, Tong J, Adams JR, Rusjan P, Houle S, Furukawa Y, Wilson AA, Boileau I.

Neurology. 2016 Jan 19;86(3):224-30. doi: 10.1212/WNL.0000000000002285. Epub 2015 Dec 30.

17.

Personality disorder symptomatology is associated with anomalies in striatal and prefrontal morphology.

Payer DE, Park MT, Kish SJ, Kolla NJ, Lerch JP, Boileau I, Chakravarty MM.

Front Hum Neurosci. 2015 Aug 31;9:472. doi: 10.3389/fnhum.2015.00472. eCollection 2015.

18.

Rapid Recovery of Vesicular Dopamine Levels in Methamphetamine Users in Early Abstinence.

Boileau I, McCluskey T, Tong J, Furukawa Y, Houle S, Kish SJ.

Neuropsychopharmacology. 2016 Mar;41(4):1179-87. doi: 10.1038/npp.2015.267. Epub 2015 Aug 31.

19.

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.

Chiuccariello L, Cooke RG, Miler L, Levitan RD, Baker GB, Kish SJ, Kolla NJ, Rusjan PM, Houle S, Wilson AA, Meyer JH.

Int J Neuropsychopharmacol. 2015 Aug 27;19(1). pii: pyv078. doi: 10.1093/ijnp/pyv078.

20.

Differential cardiovascular and hypothalamic pituitary response to amphetamine in male pathological gamblers versus healthy controls.

Zack M, Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, Warsh JJ, Kish SJ.

J Psychopharmacol. 2015 Sep;29(9):971-82. doi: 10.1177/0269881115592338. Epub 2015 Jul 7.

PMID:
26152320
21.

Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.

Tong J, Ang LC, Williams B, Furukawa Y, Fitzmaurice P, Guttman M, Boileau I, Hornykiewicz O, Kish SJ.

Neurobiol Dis. 2015 Oct;82:243-253. doi: 10.1016/j.nbd.2015.06.010. Epub 2015 Jun 21.

22.

Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.

Boileau I, Rusjan PM, Williams B, Mansouri E, Mizrahi R, De Luca V, Johnson DS, Wilson AA, Houle S, Kish SJ, Tong J.

J Cereb Blood Flow Metab. 2015 Nov;35(11):1827-35. doi: 10.1038/jcbfm.2015.133. Epub 2015 Jun 17.

23.

The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C]CURB.

Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Le Foll B, Rusjan PM, Mizrahi R, De Luca V, Zhou Q, Wilson AA, Houle S, Kish SJ, Tong J.

J Cereb Blood Flow Metab. 2015 Aug;35(8):1237-40. doi: 10.1038/jcbfm.2015.119. Epub 2015 Jun 3.

24.

[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.

Payer DE, Guttman M, Kish SJ, Tong J, Strafella A, Zack M, Adams JR, Rusjan P, Houle S, Furukawa Y, Wilson AA, Boileau I.

Mov Disord. 2015 Feb;30(2):160-6. doi: 10.1002/mds.26135. Epub 2015 Jan 14.

PMID:
25641350
25.

Parkinsonism in GTP cyclohydrolase 1-deficient DOPA-responsive dystonia.

Furukawa Y, Kish SJ.

Brain. 2015 May;138(Pt 5):e351. doi: 10.1093/brain/awu325. Epub 2014 Nov 21. No abstract available.

26.

Whole-body radiation dosimetry of 11C-carbonyl-URB694: a PET tracer for fatty acid amide hydrolase.

Boileau I, Bloomfield PM, Rusjan P, Mizrahi R, Mufti A, Vitcu I, Kish SJ, Houle S, Wilson AA, Tong J.

J Nucl Med. 2014 Dec;55(12):1993-7. doi: 10.2967/jnumed.114.146464. Epub 2014 Nov 20.

27.

Is brain gliosis a characteristic of chronic methamphetamine use in the human?

Tong J, Fitzmaurice P, Furukawa Y, Schmunk GA, Wickham DJ, Ang LC, Sherwin A, McCluskey T, Boileau I, Kish SJ.

Neurobiol Dis. 2014 Jul;67:107-18. doi: 10.1016/j.nbd.2014.03.015. Epub 2014 Apr 2.

PMID:
24704312
28.

Takotsubo cardiomyopathy associated with lithium intoxication in bipolar disorder: a case report.

Kitami M, Oizumi H, Kish SJ, Furukawa Y.

J Clin Psychopharmacol. 2014 Jun;34(3):410-1. doi: 10.1097/JCP.0b013e3182a95a27. No abstract available.

PMID:
24699038
29.

In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO.

Boileau I, Payer D, Chugani B, Lobo DS, Houle S, Wilson AA, Warsh J, Kish SJ, Zack M.

Mol Psychiatry. 2014 Dec;19(12):1305-13. doi: 10.1038/mp.2013.163. Epub 2013 Dec 10.

PMID:
24322203
30.

Greater monoamine oxidase a binding in alcohol dependence.

Matthews BA, Kish SJ, Xu X, Boileau I, Rusjan PM, Wilson AA, DiGiacomo D, Houle S, Meyer JH.

Biol Psychiatry. 2014 May 15;75(10):756-64. doi: 10.1016/j.biopsych.2013.10.010. Epub 2013 Oct 12.

31.

Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms.

Chiuccariello L, Houle S, Miler L, Cooke RG, Rusjan PM, Rajkowska G, Levitan RD, Kish SJ, Kolla NJ, Ou X, Wilson AA, Meyer JH.

Neuropsychopharmacology. 2014 Mar;39(4):973-80. doi: 10.1038/npp.2013.297. Epub 2013 Oct 24.

32.

Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO.

Payer DE, Behzadi A, Kish SJ, Houle S, Wilson AA, Rusjan PM, Tong J, Selby P, George TP, McCluskey T, Boileau I.

Neuropsychopharmacology. 2014 Jan;39(2):311-8. doi: 10.1038/npp.2013.192. Epub 2013 Aug 7.

33.

Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies.

Tong J, Meyer JH, Furukawa Y, Boileau I, Chang LJ, Wilson AA, Houle S, Kish SJ.

J Cereb Blood Flow Metab. 2013 Jun;33(6):863-71. doi: 10.1038/jcbfm.2013.19. Epub 2013 Feb 13.

34.

Mapping human brain fatty acid amide hydrolase activity with PET.

Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ, Kish SJ, Houle S, Tong J.

J Cereb Blood Flow Metab. 2013 Mar;33(3):407-14. doi: 10.1038/jcbfm.2012.180. Epub 2012 Dec 5.

35.

The D2/3 dopamine receptor in pathological gambling: a positron emission tomography study with [11C]-(+)-propyl-hexahydro-naphtho-oxazin and [11C]raclopride.

Boileau I, Payer D, Chugani B, Lobo D, Behzadi A, Rusjan PM, Houle S, Wilson AA, Warsh J, Kish SJ, Zack M.

Addiction. 2013 May;108(5):953-63. doi: 10.1111/add.12066. Epub 2013 Jan 3.

PMID:
23167711
36.

Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms.

Pifl C, Kish SJ, Hornykiewicz O.

Mov Disord. 2012 Nov;27(13):1618-24. doi: 10.1002/mds.25109. Epub 2012 Oct 4.

37.

All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study.

Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, Kish SJ.

Drug Alcohol Depend. 2012 Oct 1;125(3):290-4. doi: 10.1016/j.drugalcdep.2012.03.004. Epub 2012 Apr 13.

PMID:
22503689
38.

Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study.

Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ.

J Neurosci. 2012 Jan 25;32(4):1353-9. doi: 10.1523/JNEUROSCI.4371-11.2012.

39.

Methamphetamine use and schizophrenia: a population-based cohort study in California.

Callaghan RC, Cunningham JK, Allebeck P, Arenovich T, Sajeev G, Remington G, Boileau I, Kish SJ.

Am J Psychiatry. 2012 Apr;169(4):389-96. doi: 10.1176/appi.ajp.2011.10070937.

PMID:
22193527
40.

Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.

Sacher J, Rabiner EA, Clark M, Rusjan P, Soliman A, Boskovic R, Kish SJ, Wilson AA, Houle S, Meyer JH.

J Cereb Blood Flow Metab. 2012 Mar;32(3):443-6. doi: 10.1038/jcbfm.2011.184. Epub 2011 Dec 21.

41.

The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients.

Mann A, Miksys SL, Gaedigk A, Kish SJ, Mash DC, Tyndale RF.

Neurobiol Aging. 2012 Sep;33(9):2160-71. doi: 10.1016/j.neurobiolaging.2011.08.014. Epub 2011 Sep 29.

PMID:
21958961
42.

Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking.

Bacher I, Houle S, Xu X, Zawertailo L, Soliman A, Wilson AA, Selby P, George TP, Sacher J, Miler L, Kish SJ, Rusjan P, Meyer JH.

Arch Gen Psychiatry. 2011 Aug;68(8):817-26. doi: 10.1001/archgenpsychiatry.2011.82.

PMID:
21810646
43.

Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs.

Callaghan RC, Cunningham JK, Sykes J, Kish SJ.

Drug Alcohol Depend. 2012 Jan 1;120(1-3):35-40. doi: 10.1016/j.drugalcdep.2011.06.013. Epub 2011 Jul 26.

PMID:
21794992
44.

Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.

Tong J, Boileau I, Furukawa Y, Chang LJ, Wilson AA, Houle S, Kish SJ.

J Cereb Blood Flow Metab. 2011 Oct;31(10):2065-75. doi: 10.1038/jcbfm.2011.63. Epub 2011 Apr 27.

45.

Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain.

Tong J, Furukawa Y, Sherwin A, Hornykiewicz O, Kish SJ.

Neurobiol Dis. 2011 Feb;41(2):458-68. doi: 10.1016/j.nbd.2010.10.017. Epub 2010 Oct 26.

46.

Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders.

Callaghan RC, Cunningham JK, Sajeev G, Kish SJ.

Mov Disord. 2010 Oct 30;25(14):2333-9. doi: 10.1002/mds.23263.

PMID:
20737543
47.

Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I.

Brain. 2010 Jun;133(Pt 6):1779-97. doi: 10.1093/brain/awq103. Epub 2010 May 17.

48.

Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.

Boileau I, Houle S, Rusjan PM, Furukawa Y, Wilkins D, Tong J, Selby P, Wilson AA, Kish SJ.

Synapse. 2010 Jun;64(6):417-20. doi: 10.1002/syn.20743.

PMID:
20169578
49.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

PMID:
19903734
50.

TRPC3 protein is expressed across the lifespan in human prefrontal cortex and cerebellum.

Roedding AS, Gao AF, Wu AM, Li PP, Kish SJ, Warsh JJ.

Brain Res. 2009 Mar 13;1260:1-6. doi: 10.1016/j.brainres.2008.12.069. Epub 2009 Jan 10.

PMID:
19168035

Supplemental Content

Support Center